MRMartin A. Ritter

Martin A. Ritter

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Martin A. Ritter has a total of 94 co-authors. Here are the top co-authors by number of shared publications:

  • E. Bernd Ringelstein

    From the Department of Neurology, University of Muenster, Muenster, Germany (M.A.R., T.D., E.B.R.); and Division of Experimental and Clinical Electrophysiology, Department of Cardiology and Angiology, University Hospital of Muenster, Muenster, Germany (S.K., F.R., C.P., D.G.D., L.E.).

    8 shared publications
  • E. B. Ringelstein

    Klinik und Poliklinik für Neurologie (Direktor: Univ.-Prof. Dr. med. E. Bernd Ringelstein), Universitätsklinikum Münster

    5 shared publications
  • D. G. Nabavi

    Klinik für Neurologie, Vivantes Klinikum Neukölln, Berlin

    4 shared publications
  • Darius G. Nabavi

    From Department of Neurology (M.A.R., P.K., R.D., R. Dittrich, D.G.N., E.B.R.), University of Münster, Germany; King’s College London (P.U.H.), Division of Health and Social Care Research, London, UK; Department of Neurology (D.G.N.), Vivantes Klinikum Neukölln, Berlin, Germany; Department of Epidemiology (P.U.H.), University of Münster, Germany

    4 shared publications
  • Dirk W. Droste

    4 shared publications
  • R. Dittrich

    Klinik und Poliklinik für Neurologie (Direktor: Univ.-Prof. Dr. med. E. Bernd Ringelstein), Universitätsklinikum Münster

    4 shared publications

Latest Publications

  • Open Access

    Predictors of Atrial Fibrillation in Patients with Embolic Stroke of Unknown Etiology and Implantable Loop Recorders—Further Insights of the TRACK AF Study on the Role of ECG and Echocardiography

    by Dennis Höwel, Patrick Leitz, Gerrit Frommeyer, Martin A. Ritter, Florian Reinke, Anna Füting, Nico Reinsch, Lars Eckardt, Simon Kochhäuser, Dirk G. Dechering

    Aims—Electrocardiography (ECG) and echocardiographic left atrial (LA) parameters may be helpful to assess the risk of atrial fibrillation (AF) in embolic stroke of unknown etiology (ESUS) and could therefore guide intensity of ECG monitoring. Methods—1153 consecutive patients with ischemic stroke or transient ischemic attack (TIA) were analyzed. An internal loop recorder (ILR) was implanted in 104 consecutive patients with ESUS. Multiple morphologic P-wave parameters in baseline 12-channel ECG and echocardiographic LA parameters were measured and analyzed in patients with and without ILR-detected AF. Using logistic regression, we evaluated the predictive value of several ECG parameters and LA dimensions on the occurrence of AF. Results—In 20 of 104 (19%) patients, AF was diagnosed by ILR during a mean monitoring time of 575 (IQR 470–580) days. Patients with AF were significantly older (72 (67–75) vs. 60 (52–72) years; p = 0.001) and premature atrial contractions (PAC) were more frequently observed (40% vs. 2%; p < 0.001) during baseline ECG. All morphologic P-wave parameters did not show a significant difference between groups. There was a non-significant trend towards a larger LA volume index (31 (24–36) vs. 29 (25–37) mL/m2; p = 0.09) in AF patients. Conclusions—Age and PAC are independently associated with incident AF in ESUS and could be used as markers for selecting patients that may benefit from more extensive rhythm monitoring or ILR implantation. In our consecutive cohort of patients with ESUS, neither morphological P-wave parameters nor LA size were predictive of AF.


  • Revacept, an Inhibitor of Platelet Adhesion in Symptomatic Carotid Stenosis: A Multicenter Randomized Phase II Trial

    by Timo Uphaus, Toby Richards, Christian Weimar, Hermann Neugebauer, Sven Poli, Karin Weissenborn, Christopher Imray, Dominik Michalski, Hisham Rashid, Ian Loftus, et al.

    Background: Patients with symptomatic internal carotid artery (ICA) stenosis are at high risk of recurrent ischemic stroke and require early interventional treatment and antiplatelet therapy. Increased bleeding rates might counterbalance the periprocedural efficacy of intensified platelet inhibition. We aim to investigate, whether Revacept, a competitive antagonist of glycoprotein VI, adjunct to standard antiplatelet therapy reduces the occurrence of ischemic lesions in patients with symptomatic ICA stenosis. Methods: International, multicenter (16 sites), 3-arm, randomized (1:1:1), double-blind, and placebo-controlled study with parallel groups, including patients with symptomatic ICA stenosis. A single infusion over 20 minutes of either placebo, 40 mg or 120 mg Revacept in addition to guideline-conform antiplatelet therapy was evaluated with regard to the exploratory efficacy end point: Number of new ischemic lesions on diffusion-weighted magnetic resonance imaging after treatment initiation. Main clinical outcome was the combined safety and efficacy end point including any stroke or death, transient ischemic attack, myocardial infarction, coronary intervention, and bleeding complications during follow-up. Results: Out of 160 randomized patients, 158 patients (68±10.1 years, 24% female) received study medication (51 patients placebo, 54 patients 40 mg Revacept and 53 patients 120 mg Revacept) and were followed for 11.2±2.3 months. A total of 1.16 (95% CI, 0.88–1.53)/1.05 (95% CI, 0.78–1.42; P =0.629)/0.63 (95% CI, 0.43–0.93) new diffusion-weighted magnetic resonance imaging lesions per patient were detected in the placebo/40 mg/120 mg Revacept groups, without statistical evidence of a difference. A reduction of the combined safety and efficacy end point during the study period was observed in patients who received 120 mg (HR, 0.46 [95% CI, 0.21–0.99]; P =0.047), but not 40 mg Revacept compared with placebo (HR, 0.72 [95% CI, 0.37–1.42]; P =0.343). Conclusions: Revacept 120 mg reduced the combined safety and efficacy end point in patients with symptomatic ICA stenosis. Registration: URL: https://www.clinicaltrials.gov ; Unique Identifier: NCT01645306.


  • Occult Atrial Fibrillation in Cryptogenic Stroke

    by Martin A. Ritter, Simon Kochhäuser, Thomas Duning, Florian Reinke, Christian Pott, Dirk G. Dechering, Lars Eckardt, E. Bernd Ringelstein

    Background and Purpose—: A significant number of patients with cryptogenic stroke suffer from intermittent atrial fibrillation (iAF) which was not detected during the standard diagnostic procedures. We investigated whether implantation of an insertable cardiac monitor (ICM) is feasible in patients with cryptogenic stroke, and compared the iAF detection rate of the ICM with 7-day Holter monitoring. Methods—: Sixty patients (median age 63; interquartile range, 48.5–72 years) with acute cryptogenic stroke were included. ICM was implanted 13 days (interquartile range; 10–65 days) after the qualifying event. Seven-day Holter was performed after the ICM was implanted. Results—: The iAF was detected by the ICM in 10 patients (17%; 95% CI, 7% to 26%). Only 1 patient (1.7%; 95% CI, 0% to 5%) had iAF during 7-day Holter monitoring as well ( P =0.0077). Episodes of iAF lasting 2 minutes or more were detected 64 (range, 1–556) days after implantation. There were no recurrent strokes during the observation period. The implantation procedure was well tolerated with no adverse events; the daily data transmission protocol was easy to handle by the patients. Conclusions—: ICM implantation for the detection of iAF during outpatient follow-up is feasible in patients with cryptogenic stroke. ICMs offer a much higher diagnostic yield than 7-day Holter monitoring.


  • Open Access

    Ultrasound in spontaneous cervical artery dissection

    by Ralf Dittrich, Martin A. Ritter, Erich B. Ringelstein


  • Neurosonografie in der neurologischen Notfall- und Intensivmedizin: Monitoring des erhöhten intrakraniellen Druckes, Hirntoddiagnostik und Untersuchung der zerebralen Autoregulation – Teil 2

    by J. U. Harrer, J. Eyding, M. Ritter, U. Schminke, G. Schulte-Altedorneburg, M. Köhrmann, M. Nedelmann, F. Schlachetzki

    Parenchymdiagnostik bei erhöhtem intrazerebralem Druck/zum Monitoring einer Mittellinienverlagerung, bei ischämischen und hämorrhagischem Schlaganfall. Grundlagen der Orbitasonografie. Hirntoddiagnostik. Zerebrale Autoregulation und zerebrovaskuläre Reservekapazität.


  • Zukünftige Versorgungskonzepte des Schlaganfalls

    by M. A. Ritter, R. Dittrich, O. Busse, D. G. Nabavi, E. B. Ringelstein

    Moderne Schlaganfallversorgung findet auf zertifizierten Stroke Units statt. Aufgrund von Veränderungen der Altersstruktur der Bevölkerung und aus wirtschaftlichen Gründen wird sich die zukünftige Stroke-Unit-Landschaft weiter ändern. Der „Eckpfeiler der Versorgung” bleibt die zertifizierte Stroke Unit. Diese wird sich allerdings weiter ausdifferenzieren. Neben den regionalen und überregionalen Stroke Units werden „comprehensive Stroke Units“ gefördert, die den frühen rehabilitativen Charakter des skandinavischen Behandlungsansatzes besser umsetzen können. Spezialambulanzen für neurovaskuläre Erkrankungen werden eine integrierte Versorgung durch ein Expertenteam ermöglichen. In Häusern der Spitzenversorgung werden sich „Neurovaskuläre Zentren“ bilden, die auf die noch stärkere Einbindung aller Disziplinen ausgerichtet sind, die sich an der Diagnostik und Behandlung zerebrovaskulärer Erkrankungen beteiligen. Ziele dieser Zentren sind insbesondere die Bewältigung komplexerer Fälle, die interdisziplinäre Festlegung evidenzbasierter Indikationen, die Durchführung großer klinischer Studien sowie die effiziente Versorgung seltener neurovaskulärer Krankheiten. Diese Veränderungen werden durch zunehmenden Einsatz moderner Medien unterstützt, sowohl in der Akutversorgung, beispielsweise durch Telekonsile und Teleradiologie als auch im Monitoring vitaler Patientenparameter durch Datenanalyse über schnelle Internetverbindungen. Auch die Nachfrage nach neuroradiologischen Interventionen wird zunehmen; hier wird es v. a. darauf ankommen, gesicherte Indikationen zu definieren. Konzepte zur prähospitalen Versorgung, evtl. einschließlich prähospitaler Lysetherapie von Schlaganfallpatienten, werden davon abhängig sein, wie effektiv sie sind. The state-of the art management of stroke patients is treatment on a certified stroke unit. Demographical changes and increasing morbidity will increase both, the number of stroke patients and the complexity of the cases. Increasing patient numbers in an era of economical restraints require highly effective services. The “stroke unit” concept will be diversified in the future to serve stroke patients on various levels: basic stroke units, stroke centres and comprehensive stroke units will be established, in some big hospitals Neurovascular centres will be implemented in which highly complex cases can be treated in quite high numbers. The strict separation of the inpatient and the outpatient treatment in Germany will be broken up by centres that deliver integrated stroke services. Telemedicine will play a growing role in stroke medicine. Telemedicine wil be used as part of the acute treatment by teleconsults and teleradiology. Furthermore, exchange of patient data by fast and secure internet lines, e.g., for cerebral imaging or external ECG analysis to detect atrial fibrillation, will be used more extensively. The demand for neuroradiological interventions will increase. Therefore it will be mandatory to define clear indications as to which patients are likely to benefit from complex and costly procedures. The indications and costs for prehospital stroke services such as the STEMO will have to be defined.


  • Klinisch stumme Hirninfarkte

    by M.A. Ritter, R. Dittrich, E.B. Ringelstein


  • Open Access

    Heart rate monitoring on the stroke unit. What does heart beat tell about prognosis? An observational study

    by Martin A Ritter, Anne Rohde, Peter U Heuschmann, Rainer Dziewas, Jörg Stypmann, Darius G Nabavi, Bernd E Ringelstein

    Guidelines recommend maintaining the heart rate (HR) of acute stroke patients within physiological limits; data on the frequency and predictors of significant deviations from these limits are scarce.


  • Welcher Patient mit chronischem Vorhofflimmern kommt in Frage für einen perkutanen Vorhofohrverschluss?

    by P Wagdi, M Ritter, F Salzer

    Gut 3% der über 65-jährigen Menschen erkranken an Vorhofflimmern; in der Schweiz sind somit mehr als 30'000 Personen betroffen. Etwa 30% der Patienten mit chronischem Vorhofflimmern erleiden mindestens einmal einen zerebrovaskulären Insult. Das chronische Vorhofflimmern ist verantwortlich für 15 - 20% aller zerebrovaskulären Insulte. Folgende Faktoren bilden den sog. CHADS2-Score und sind Prädiktoren für einen, durch Vorhofflimmern bedingten zerebrovaskulären Insult: Herzinsuffizienz, Hypertonie, Alter >75 Jahren, Diabetes mellitus, Status nach zerebrovaskulärem Insult. Eine gut eingestellte orale Antikoagulation ist die Behandlung der Wahl zur Prophylaxe thrombo­embolischer Ereignisse bei Patienten mit einem CHADS2-Score >2. Der perkutane Verschluss des linken Vorhofohrs bildet eine valable Alternative bei älteren Patienten mit Kontraindikation zur oralen Antikoagulation. Eine ausgewogene Information über die Methode sollte dazu beitragen, einerseits nicht indizierte Eingriffe zu vermeiden und andererseits keine falschen Erwartungen zu wecken. La fibrillation auriculaire affecte environ 3% des personnes âgées de plus de 65 ans. Approximativement 30% des malades atteints de fibrillation auriculaire chronique présentent au moins un accident vasculaire cérébral. D'un autre côté, la fibrillation auriculaire est responsable de 15 à 20% de l'ensemble des accidents cérébro-vasculaires. Chez les malades avec fibrillation auriculaire chronique, un score CHADS2 de 3 points ou plus représente un élément prédictif fiable d'un futur accident vasculaire cérébral. L'anticoagulation orale reste le traitement de choix pour prévenir les complications thromboemboliques. La fermeture percutanée de l'appendice auriculaire gauche est une approche prometteuse et probablement une alternative valable chez les malades âgés intolérants à l'anticoagulation orale. Atrial fibrillation affects about 3% of all persons older than 65 years of age. About 30% of patients with chronic atrial fibrillation suffer from at least one cerebrovascular accident. On the other hand, atrial fibrillation is responsible for 15 - 20% of all cerebrovascular insults. A CHADS2 score of 3 points or more has been found to be a reliable predictor of future cerebrovascular events in patients with chronic atrial fibrillation. Oral anticoagulation remains the mainstay of treatment to prevent thromboembolic complications. Percutaneous closure of the left atrial appendage is a promising approach and probably a valid alternative in older patients intolerant to oral anticoagulation.


  • Open Access

    Response to the letter by Dr. Sharma

    by Martin A. Ritter, R. Dittrich, N. Thoenissen, E. B. Ringelstein, D. G. Nabavi